{"article_title": "Potential Gel Treatment for Inflammatory Bowel Disease", "article_keywords": ["inflammatory", "drugs", "bowel", "ibd", "disease", "drug", "inflammation", "potential", "treatment", "team", "womens", "hydrogel", "gel"], "article_url": "http://www.hcplive.com/medical-news/potential-gel-treatment-for-inflammatory-bowel-disease", "article_text": "Potential Gel Treatment for Inflammatory Bowel Disease\n\nHydrogel had been reported to successfully treat targeted tissues in patients with inflammatory bowel disease (IBD).A team of researchers from Brigham and Women\u2019s Hospital (BWH) recently concluded in Science Translational Medicine, that lab-created hydrogel could potentially serve to deliver drugs in IBD through enemas specifically targeting inflamed tissues.The experts used US approved ascorbyl plamitate (AP) and corticosteroid drugs routinely used for IBD treatment to create the gel that would only disassemble to release the drug on contact with specific IBD enzymes.Using mice models, the researchers noticed the drugs delivered through hydrogels diminished inflammation more effectively (5-10 times lower concentrations of the drugs) than through treatment with traditional enemas.The team found that the hydrogel worked by attaching itself to inflammation sites, gradually releasing drug doses over an extended period of time.Jeff Karp, PhD, associate professor Brigham and Women's Hospital, commented, \u201cWe realized that if we could develop a disease-targeted hydrogel system that rapidly attaches to ulcers and slowly release drugs at the site of inflammation, then we could create a better way to deliver medicine only where the drug is needed.\u201dJoerg Ermann, MD, rheumatologist, BWH, concluded, \u201cWe have found that the hydrogel approach works well in mice and our data look promising that it might also be an effective strategy in humans with inflammatory bowel disease of the colon.\u201dAs such, the research team surmised this discovery could eventually pave the road for an enema \u2013 likely one without systemic side effects \u2013 that IBD patients would only have to use once a week.", "article_metadata": {"description": "Hydrogel had been reported to successfully treat targeted tissues in patients with inflammatory bowel disease (IBD).", "og": {"site_name": "MD Magazine", "description": "Hydrogel had been reported to successfully treat targeted tissues in patients with inflammatory bowel disease (IBD).", "title": "Potential Gel Treatment for Inflammatory Bowel Disease", "url": "http://www.hcplive.com/medical-news/potential-gel-treatment-for-inflammatory-bowel-disease", "image": "https://s3.amazonaws.com/hcplive/v1_media/_upload_image/_thumbnails/bluecolon.jpg", "type": "Article"}, "msapplication-TileColor": "#ffffff", "msapplication-TileImage": "https://s3.amazonaws.com/hcplive/v2_media/_core/favi/ms-icon-144x144.png", "keywords": "gastroenterology, inflammatory bowel disease, IBD, internal medicine, hydrogel, corticosteroids, pharmacy", "theme-color": "#ffffff"}, "_id": "\"57477af46914bd0286fe19b9\"", "article_summary": "Potential Gel Treatment for Inflammatory Bowel DiseaseHydrogel had been reported to successfully treat targeted tissues in patients with inflammatory bowel disease (IBD).A team of researchers from Brigham and Women\u2019s Hospital (BWH) recently concluded in Science Translational Medicine, that lab-created hydrogel could potentially serve to deliver drugs in IBD through enemas specifically targeting inflamed tissues.The experts used US approved ascorbyl plamitate (AP) and corticosteroid drugs routinely used for IBD treatment to create the gel that would only disassemble to release the drug on contact with specific IBD enzymes.Using mice models, the researchers noticed the drugs delivered through hydrogels diminished inflammation more effectively (5-10 times lower concentrations of the drugs) than through treatment with traditional enemas.The team found that the hydrogel worked by attaching itself to inflammation sites, gradually releasing drug doses over an extended period of time.Jeff Karp, PhD, associate professor Brigham and Women's Hospital, commented, \u201cWe realized that if we could develop a disease-targeted hydrogel system that rapidly attaches to ulcers and slowly release drugs at the site of inflammation, then we could create a better way to deliver medicine only where the drug is needed.\u201dJoerg Ermann, MD, rheumatologist, BWH, concluded, \u201cWe have found that the hydrogel approach works well in mice and our data look promising that it might also be an effective strategy in humans with inflammatory bowel disease of the colon.\u201dAs such, the research team surmised this discovery could eventually pave the road for an enema \u2013 likely one without systemic side effects \u2013 that IBD patients would only have to use once a week."}